Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

And, if all goes well, over the next five years as well.

This biotech has candidates in late-stage clinical development.

Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and ...

Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.

Plenty of analysts on Wall Street think so. The company boasts an average price target of $93.39 (according to Yahoo! Finance ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Other useful metrics include insider buying and levels of short activity, which offer stronger predictive signals than ...

Biotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make ...